How does hla typing work

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: HLA typing identifies specific human leukocyte antigen (HLA) genes on chromosome 6, which encode proteins critical for immune system function. The process involves extracting DNA from blood or tissue samples and using techniques like PCR-SSP, PCR-SSO, or next-generation sequencing to analyze HLA alleles. HLA typing is essential for organ and stem cell transplantation, with over 40,000 transplants performed annually worldwide requiring HLA matching. The first HLA antigen was discovered in 1958 by Jean Dausset, leading to the Nobel Prize in Physiology or Medicine in 1980.

Key Facts

HLA genes are located on chromosome 6p21.3 and are the most polymorphic in the human genome, with over 35,000 known alleles
HLA matching reduces transplant rejection risk; a 10/10 HLA match in bone marrow transplants improves survival rates by 20-30% compared to mismatches
The first international HLA workshop was held in 1964, standardizing typing methods and nomenclature
Next-generation sequencing (NGS) for HLA typing can identify alleles with 99.9% accuracy and became clinically available around 2010
HLA-B27 is associated with autoimmune diseases like ankylosing spondylitis, affecting approximately 90% of patients

Overview

Human leukocyte antigen (HLA) typing is a laboratory technique used to identify specific variants of HLA genes, which play a crucial role in the immune system by presenting antigens to T-cells. Discovered in 1958 by French immunologist Jean Dausset, who identified the first HLA antigen (MAC, later HLA-A2), HLA typing has evolved significantly. The HLA system, encoded by genes on chromosome 6p21.3, is the most polymorphic in the human genome, with over 35,000 known alleles as of 2023. Historically, serological methods using antibodies were employed from the 1960s to 1990s, but these were limited by specificity. The field advanced with the introduction of molecular techniques in the 1980s, such as restriction fragment length polymorphism (RFLP) analysis, followed by polymerase chain reaction (PCR)-based methods in the 1990s. Today, HLA typing is standardized by organizations like the World Health Organization (WHO) and the International Society for Blood and Marrow Transplantation (ISBMT), with applications extending beyond transplantation to disease association studies and pharmacogenomics.

How It Works

HLA typing begins with sample collection, typically from blood or buccal swabs, to extract DNA. The process involves several molecular techniques: PCR-sequence-specific priming (PCR-SSP) uses primers that bind to specific HLA alleles, amplifying target sequences for detection via gel electrophoresis. PCR-sequence-specific oligonucleotide (PCR-SSO) probing hybridizes amplified DNA with labeled probes to identify alleles through luminescence or fluorescence. More advanced methods include sequence-based typing (SBT), which sequences exon regions of HLA genes using Sanger sequencing, and next-generation sequencing (NGS), introduced clinically around 2010, which provides high-resolution typing by sequencing entire HLA genes with 99.9% accuracy. For example, NGS can analyze over 1,000 samples simultaneously, identifying rare alleles. The typing process targets key HLA loci: HLA-A, -B, -C (Class I) and HLA-DR, -DQ, -DP (Class II). Results are interpreted using databases like the IPD-IMGT/HLA Database, which catalogs over 35,000 alleles, and reported as allele names (e.g., HLA-A*02:01). Quality control involves validation with reference samples and proficiency testing through programs like the American Society for Histocompatibility and Immunogenetics (ASHI).

Why It Matters

HLA typing is vital for organ and hematopoietic stem cell transplantation, where matching donors and recipients reduces rejection risks; for instance, a 10/10 HLA match in bone marrow transplants can improve survival rates by 20-30%. Annually, over 40,000 transplants worldwide rely on HLA typing to prevent graft-versus-host disease (GVHD) and improve outcomes. Beyond transplantation, it aids in diagnosing autoimmune diseases, such as the link between HLA-B27 and ankylosing spondylitis, affecting about 90% of patients. In pharmacogenomics, HLA typing predicts adverse drug reactions, like HLA-B*57:01 association with abacavir hypersensitivity, preventing severe side effects in HIV treatment. The technology also supports research in cancer immunotherapy, where HLA profiles guide personalized vaccines. Economically, HLA typing represents a multi-billion dollar industry, with global market growth driven by increasing transplant rates and precision medicine adoption.